Due to health issues, this site is no longer maintained and will be shut down shortly.

DRMAW Dermata Therapeutics, Inc. - Warrant

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.  This security was issued by Dermata Therapeutics, Inc., whose common stock symbol is DRMA.

$0.03  +0.01 (27.27%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/13/2021
Outstanding shares:  1,875,000
Average volume:  9,305
Market cap:   $4,012,240
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy